Among the 78 BLs in this series, an additional five had RHOA mutations resulting in a total incidence of 7/82 (8.5%) with c.14G>A (p.R5Q) being present in three cases.
We also found rs2071346 (G>T) variant genotype carriers were subjected to higher risk of anemia (GT <i>vs</i> GG, OR=1.665, P=0.022) and thrombocytopenia (GT <i>vs</i> GG, OR=1.685, P=0.035).
In addition, rs4645948 (C>T) was conferred with increased risk of anemia (CT <i>vs</i> CC, OR=2.152, P=0.001) and severe leukopenia (CT <i>vs</i> CC, OR=1.893, P=0.034) for NPC patients receiving chemoradiotherapy.
Here, we analysed the influence of the rare c-MYC Asn11Ser polymorphism on familial breast cancer risk by performing a case-control study with a Polish (cases n = 349; controls n = 441) and a German (cases n = 356; controls n = 655) study population.
A joint analysis of the Polish and the German study population revealed a 54% increased risk for breast cancer associated with the heterozygous Asn11Ser variant (OR = 1.54, 95% CI 1.05-2.26, p = 0.028).
Among the 78 BLs in this series, an additional five had RHOA mutations resulting in a total incidence of 7/82 (8.5%) with c.14G>A (p.R5Q) being present in three cases.
Among the 78 BLs in this series, an additional five had RHOA mutations resulting in a total incidence of 7/82 (8.5%) with c.14G>A (p.R5Q) being present in three cases.
We also identified a SNP achieving array wide significance (MYC: rs2070583, allele frequency 0.02, P = 8.1 × 10(-8)), but the association did not replicate in an additional 8,059 African Americans (577 events) from the WHI, HealthABC and GeneSTAR studies, and in a meta-analysis of 5 cohort studies of European ancestry (24,024 individuals including 1,570 cases of MI and 2,406 cases of CHD) from the CHARGE Consortium.
In addition, rs4645948 (C>T) was conferred with increased risk of anemia (CT <i>vs</i> CC, OR=2.152, P=0.001) and severe leukopenia (CT <i>vs</i> CC, OR=1.893, P=0.034) for NPC patients receiving chemoradiotherapy.